Svenningsson Mads M, Svingen Gard F T, Lysne Vegard, Ueland Per M, Tell Grethe S, Pedersen Eva R, Dhar Indu, Nilsen Dennis W, Nygård Ottar
Haukeland University Hospital, Dept of Heart Disease, Bergen, Norway.
Haukeland University Hospital, Dept of Heart Disease, Bergen, Norway.
Int J Cardiol. 2020 Oct 15;317:75-80. doi: 10.1016/j.ijcard.2020.05.010. Epub 2020 May 8.
BACKGROUND/AIM: Plasma total homocysteine (tHcy) is elevated in patients with persistent vs. paroxysmal atrial fibrillation (AF), and has been related to increased risk of new-onset AF. Homocysteine is degraded to cystathionine (Cysta) and cysteine (Cys). All three metabolites have been linked to potential proarrhythmic traits such as inflammation and atrial fibrosis. We evaluated the prospective association between these metabolites and new-onset AF among patients with suspected stable angina pectoris.
Information regarding AF was obtained by linking patient data to national health registries. Risk associations were explored by Cox regression and potential improvements in risk reclassification were calculated by the continuous net reclassification index (NRI > 0).
At baseline, 3535 patients without any prior history of AF were included. During median follow-up of 7.4 years, 392 patients (10.2%) were registered with incident AF. Higher plasma tHcy and tCys were associated with increased risk of incident AF [age and gender adjusted HRs (95% CI) per 1 log transformed SD 1.23 (1.12-1.35) and 1.23 (1.11-1.38)]; multivariate adjustment yielded similar results. Plasma tHcy and tCys also improved reclassification of patients (NRI > 0 (95% CI)) for tHcy 0.118 (0.02-0.22) and tCys 0.107 (0.002-0.21). No association was seen between plasma Cysta and incident AF.
Plasma tHcy and tCys, but not Cysta, were associated with, and improved risk classification of, new-onset AF among patients with stable angina pectoris. Our results motivate further studies to explore the relationship between homocysteine metabolism and cardiac arrhythmias.
背景/目的:持续性心房颤动(AF)患者的血浆总同型半胱氨酸(tHcy)水平高于阵发性AF患者,且与新发AF风险增加有关。同型半胱氨酸可降解为胱硫醚(Cysta)和半胱氨酸(Cys)。这三种代谢产物均与炎症和心房纤维化等潜在的促心律失常特征有关。我们评估了这些代谢产物与疑似稳定型心绞痛患者新发AF之间的前瞻性关联。
通过将患者数据与国家健康登记处相链接来获取AF相关信息。采用Cox回归探讨风险关联,并通过连续净重新分类指数(NRI>0)计算风险重新分类的潜在改善情况。
基线时,纳入3535例无AF既往史的患者。在中位随访7.4年期间,392例患者(10.2%)登记发生新发AF。较高的血浆tHcy和tCys与新发AF风险增加相关[年龄和性别校正的每1个对数转换标准差的HR(95%CI)分别为1.23(1.12 - 1.35)和1.23(1.11 - 1.38)];多变量调整产生相似结果。血浆tHcy和tCys也改善了患者的重新分类(NRI>0(95%CI)),tHcy为0.118(0.02 - 0.22),tCys为0.107(0.002 - 0.21)。未观察到血浆Cysta与新发AF之间存在关联。
血浆tHcy和tCys而非Cysta与稳定型心绞痛患者的新发AF相关,并改善了其风险分类。我们的结果促使进一步研究探索同型半胱氨酸代谢与心律失常之间的关系。